Acetaldehyde Diethyl Acetal CAS 3616-56-6 Puritas >99.0% (GC) Afatinib Dimaleate Intermedia Factory
Ruifu Chemical Supple intermedia de Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
acetaldehyda Diethyl acetalis CAS 3616-56-6
trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-75
Diethylphosphonoaceticum acidum CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Nomen chemicum | (Dimethylamino) acetaldehyde Diethyl acetal |
Synonyma | 2,2-Diethoxy-N,N-Dimethylethylamine;N-(2,2-Diethoxyethyl)dimethylamine;2,2-Diethoxy-N,N-Dimethylethan-1-Amine |
CAS Number | 3616-56-6 |
CATTUS Number | RF-PI2031 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C8H19NO2 |
M. Pondus | 161.25 |
Sensibilitas | umorem Sensitivum |
Ferveret | 60℃/5 mmHg |
Mico punctum | 45℃ |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Hyalina liquida |
Puritas / Analysis Methodus | >99.0% (GC) |
Index refractivus N20/D | 1.410~1.414 |
Gravitas Imprimis (20/20℃) | 0.865~0.870 |
Proton NMR Spectrum | Conformat ut Structure |
Totalis immunditias | <1.00% |
Metalla gravia (ut Pb) | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Pharmaceutical Intermedia;Afatinib Dimaleate;Sumatriptan |
sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
acetaldehyda Diethyl acetalis (CAS: 3616-56-6) adhibetur pro intermediis pharmaceuticis.acetaldehyde Diethyl acetal in synthesi Afatinib Dimaleate (CAS: 850140-73-7), Sumatriptan (CAS: 103628-46-2).Afatinib (nomen artis Gilotrif in US et Giotrif in Europa, antea Tomtovok et Tovok) medicamentum probatum est in Civitatibus Foederatis, Europa, Taiwan, Mexici, Chile et Iaponia necnon in aliis regionibus ad curationem primi-lineae aegris distinctis. genera metastaticae (EGFR mutationis positivae) non parvae cellae pulmonis carcinomatis (NSCLC), a Boehringer Ingelheim evoluta.Afatinib agit inhibitor irreversibilis covalentoris tyrosini kinases epidermalis receptantis aucti (EGFR) et erbB-2 (HER2).Sumatriptan primus triptanus probatus est (1991) pro theacutis curatione capitis cephalea.Bioavailbilitatem infima inter omnes triptans habet propter humilitatem suam.Praeparatio plurium dosagenarum variarum (ie, tabulae oralis, iniectio SC, formulae nasi imbre, et suppositorium) flexibilitatem tailoringtherapiae ad necessitates singulorum aegrorum permittit, ita sumatriptans medicamentum valde utilem faciens ad acutum cephalaeum curationi. capitis doloribus.Sumatriptan quoque modum fastigium actionis per SC iniectionem vel imbrem nasi administrationis habet.